Clinical trial for novel minimally invasive synovial biopsy in rheumatic diseases

Clinical trial for novel minimally invasive synovial biopsy in rheumatic diseases - Clinical trial for novel minimally invasive synovial biopsy in rheumatic diseases

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000018076

Enrollment

Registered

2015-06-24

Start date

2014-04-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatic diseases

Interventions

Ultrasonography guided synovial needle biopsy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Arthritic patients who have at least 1 swollen joint and require pathological examination for diagnosis and give written informed consent before study.

Exclusion criteria

Exclusion criteria: Patients who dismissed as inadequate for medical reason by attending doctor.

Design outcomes

Primary

Measure	Time frame
1. Examination for safety Early complication (30 minute after biopsy): Examine presence/absence of complication such as bleeding, neural symptom. Late complication(5~7 days after biopsy): Examine infection and complication of biopsy needle inserting portion . 2. Examination for tolerability: Evaluate pain, swelling, stiffness in 3 points; before biopsy, 30 minute after biopsy, 5-7 days after biopsy using by visual analog scale. 3. Examination for efficacy and reliability of tissue samples: Count and measuring the size of sample and perform general histological and biological examination. Surplus samples were cultured and analyzed gene and protein expression in our laboratory.	—

Measure

Time frame

1. Examination for safety Early complication (30 minute after biopsy): Examine presence/absence of complication such as bleeding, neural symptom. Late complication(5~7 days after biopsy): Examine infection and complication of biopsy needle inserting portion . 2. Examination for tolerability: Evaluate pain, swelling, stiffness in 3 points; before biopsy, 30 minute after biopsy, 5-7 days after biopsy using by visual analog scale. 3. Examination for efficacy and reliability of tissue samples: Count and measuring the size of sample and perform general histological and biological examination. Surplus samples were cultured and analyzed gene and protein expression in our laboratory.

—

Countries

Japan

Contacts

Public ContactKatsuya Suzuki

Keio University School of Medicine Division of Rheumatology

katsuyas@z5.keio.jp03-3353-1211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026